For comments, suggestions
Created with Raphaël 2.1.0 14.12.2017 Filing date 12.07.2019 Validation fee payment 31.12.2019 (A1) Patent application published 03.11.2022 AGEPI application filing date 31.12.2022 (T2) Translation of the validated European patent 01.05.2025 14.12.2025 Valid until 15.12.2026 Renewal fee to be paid until 14.12.2037 Patent will expire on

Patent in force


(210)Number of the EPO application17832405
(220)Filing date of the EPO application2017.12.14
(80)EPO patent specification publication (B)EPB nr. 36/2022, 2022.09.07
(110)EPO patent number3554554
(11)Number of the documentMD 3554554 T2
(21)Number of the applicatione 2019 1208
(71)Name(s) of applicant(s), code of the countrySAREPTA THERAPEUTICS, INC., US;
(72)Name(s) of inventor(s), code of the countryPASSINI Marco A., US;
HANSON Gunnar J., US;
(73)Name(s) of owner(s), code of the countrySAREPTA THERAPEUTICS, INC., US;
(54)Title of the inventionExon skipping oligomer conjugates for muscular dystrophy
(13)Kind-of-document code T2
(51)International Patent Classification A61K 47/64 (2017.01.01); A61P 21/00 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2019.12.31
(49)Date of publication of the translation of the validated European patent specification2022.12.31
(30)Priority201662436199 P, 2016.12.19, US; 201762443481 P, 2017.01.06, US; 201762479177 P, 2017.03.30, US; 201762562119 P, 2017.09.22, US
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/US2017/066351, 2017.12.14
(87)International publicationWO 2018/118627, 2018.06.28
Up
/Inventions/details/3554554